Table 3 Application of LPHNPs for prostate cancer
Sr. No | Lipid component | Polymer component | Targeting moiety | Drug | In vitro | In vivo | Ref |
|---|---|---|---|---|---|---|---|
1 | Lecithin, DSPE-PEG, | PLGA | PSMA targeting A10 aptamer | DTX | PC3 | _ | [242] |
2 | DSPE-PEG-Malemide, PSC and cholesterol | PLGA | CD44 antibodies | Salinomycin | DU145 PC and 22RV1 | _ | [243] |
3 | Cholesterol and PSC and DSPE-PEG-2000, | PLGA | _ | DTX and sphingosine kinase 1 (SK1) FTY720 (fingolimod) | PC3 and DU145 | NOD SCID gamma (NSG) immunodeficient nude mice | [245] |
4 | Lecithin and DSPE-PEG | PLGA | _ | CUR and DTX | PC3 | BALB/c nude mice | [244] |
5 | SPC | PLGA-PEG-COOH | PSMA aptamer | CUR and CTX | LNCaP and PC3 | BALB/c nude mice | [246] |